Please login to the form below

Not currently logged in

Jane Osbourn to chair BIA board

VP of R&D atMedimmune to chair BioIndustry Association board
Jane osbourn BIA

Jane Osbourn will be the new chair of the BioIndustry Associaton (BIA) board, effective January 2016.

Osbourn has 25 years of experience in the life sciences sector and currently serves as site leader and VP of research at MedImmune.

She said: “It has been my privilege to serve as a member of the BIA board since January 2014 and I am delighted to be taking over as chair during a period of such great opportunity for our industry.

“I am also very pleased to welcome our newly elected board members, who are recognised leaders and bring a diversity of ideas and backgrounds to the team.”

The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals. Additionally Andrew Lightfood of Peptinnovate and Neil Murray of RedX Pharma will be joining.

Celia Caulcott, vice-provost of UCL Business has also been re-elected to the board.

Steve Bates, BIA chief executive added: “2015 has been a great year for the industry and I look forward to working with Jane and the board to build on this success in 2016. “I am confident that our multi-disciplined and diverse board will help to steer the industry through future challenges and represent the interests of all sizes of company in our sector.”

28th October 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...